Announcements Trials
Browse Landscape

Phase

Phase 4 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Stomach Neoplasms 2Rectal Neoplasms 1Prostatic Neoplasms 1Osteoarthritis 1Glioma 1Colorectal Neoplasms 1Colonic Neoplasms 1Cancer Pain 1Brain Stem Neoplasms 1Brain Neoplasms 1Barrett Esophagus 1Advanced Non-small Cell Lung Cancer 1Adenomatous Polyposis Coli 1

Interventions

Celecoxib 6Biopsy 5Sulindac 4Specimen Handling 3Eflornithine 3Curcumin 3Ursodeoxycholic Acid 2Surveys and Questionnaires 2Sirolimus 2Sigmoidoscopy 2Gastroscopy 2Erythromycin 2Erlotinib Hydrochloride 2Endoscopy, Gastrointestinal 2Endoscopy 2Colonoscopy 2trifluridine tipiracil drug combination 1rofecoxib 1obeticholic acid 1guselkumab 1Thiamine 1Suppositories 1Probiotics 1Polymorphism, Single-Stranded Conformational 1Polymerase Chain Reaction 1Pharmaceutical Preparations 1Oxaliplatin 1Nivolumab 1Niclosamide 1Metformin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Adenomatous Polyposis Coli × rofecoxib × Clear all
NCT00140894 2019-09-20

A Study of Rofecoxib in Familial Adenomatous Polyposis (FAP) (0966-205)(TERMINATED)

Merck Sharp & Dohme LLC

Phase 4 Terminated
62 enrolled
Gastrointestinal

Cancer Pain, Osteoarthritis, Adenomatous Polyposis Coli

Data powered by HemOnc (CC BY 4.0) Colophon âš¡